We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of MDD Management in Andalusia (PismaEP)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01510886
First Posted: January 18, 2012
Last Update Posted: August 13, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
January 12, 2012
January 18, 2012
August 13, 2014
June 2012
September 2013   (Final data collection date for primary outcome measure)
  • Number of Visits to Primary Care [ Time Frame: From Jan 2010 to Jan 2011 ]
  • Number of Visits to Secondary Care [ Time Frame: From Jan 2010 to Jan 2011 ]
  • Number of Referrals [ Time Frame: From Jan 2010 to Jan 2011 ]
Same as current
Complete list of historical versions of study NCT01510886 on ClinicalTrials.gov Archive Site
  • Demographics [ Time Frame: From Jan 2010 to Jan 2011 ]
  • Type of site [ Time Frame: From Jan 2010 to Jan 2011 ]
  • Type of therapeutic strategy [ Time Frame: From Jan 2010 to Jan 2011 ]
  • Type of disease [ Time Frame: From Jan 2010 to Jan 2011 ]
  • Severity of disease [ Time Frame: From Jan 2010 to Jan 2011 ]
Same as current
Not Provided
Not Provided
 
Assessment of MDD Management in Andalusia
Assessment of MDD Management Strategies in Andalusia: A Sub-analysis of the PismaEP Study
The main objectives of this study are to describe medical professionals responsible of the management of patients with MDD in a representative region of Andalusia (in terms of type of sites managing the disease, and referral to SC criteria); Describe MDD patient characteristics at inclusion in the PISMA-Ep Study; and to evaluate those factors associated to a higher incidence of referral from PC to SC.
Assessment of MDD management strategies in Andalusia: A Sub-analysis of the PismaEP Study
Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
MDD patients treated in Primary Care or Secondary Care in the Region of Granada and recruited for the PISMA-Ep Study
MDD Management Strategies
Not Provided
1
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5309
September 2013
September 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • MDD Diagnosis Participants of the PismaEP study 18 yo. or older

Exclusion Criteria:

  • No specific exclusion criteria
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT01510886
NIS-NES-XXX-2011/3
PismaEP
No
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Jorge Cervilla, MD Hospital San Cecilio
AstraZeneca
August 2014